AbbVie Inc. (ABBV)
Largest Insider Buys in Sector
ABBV Stock Price History Chart
ABBV Stock Performance
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with …
Insider Activity of AbbVie Inc.
Over the last 12 months, insiders at AbbVie Inc. have bought $0 and sold $143.55M worth of AbbVie Inc. stock.
On average, over the past 5 years, insiders at AbbVie Inc. have bought $667,072 and sold $84.6M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 750 shares for transaction amount of $51,750 was made by Durkin Brian L (VP, Controller) on 2020‑03‑30.
List of Insider Buy and Sell Transactions, AbbVie Inc.
| 2024-08-05 | Sale | EXECUTIVE CHAIRMAN OF BOARD | 66,500 0.0038% | $186.52 | $12.4M | +5.36% | ||
| 2024-07-17 | Sale | EXECUTIVE CHAIRMAN OF BOARD | 282,845 0.016% | $175.00 | $49.5M | +10.59% | ||
| 2024-03-20 | Sale | EVP, CHIEF BUS/STRAT OFFICER | 21,082 0.0012% | $176.30 | $3.72M | +0.02% | ||
| 2024-03-18 | Sale | EVP, CHIEF COMMERCIAL OFFICER | 58,949 0.0033% | $178.79 | $10.54M | -0.96% | ||
| 2024-03-01 | Sale | EVP, CHIEF HR OFFICER | 75,680 0.0042% | $177.27 | $13.42M | -0.22% | ||
| 2024-02-29 | Sale | PRES & CHIEF OPERATING OFFICER | 68,879 0.0039% | $176.45 | $12.15M | +1.46% | ||
| 2024-02-29 | Sale | EVP, GC AND SECRETARY | 9,891 0.0006% | $177.39 | $1.75M | +1.46% | ||
| 2024-02-29 | Sale | SVP, CONTROLLER | 5,144 0.0003% | $176.65 | $908,688 | +1.46% | ||
| 2024-02-28 | Sale | CHAIRMAN OF THE BOARD AND CEO | 138,616 0.0078% | $177.27 | $24.57M | +0.25% | ||
| 2024-02-23 | Sale | EVP, GC AND SECRETARY | 13,753 0.0008% | $177.51 | $2.44M | +0.24% | ||
| 2024-02-23 | Sale | EVP, CHIEF FINANCIAL OFFICER | 14,140 0.0008% | $177.44 | $2.51M | +0.24% | ||
| 2024-02-21 | Sale | EVP, CHIEF OPERATIONS OFFICER | 52,870 0.003% | $173.71 | $9.18M | +1.89% | ||
| 2023-12-26 | Sale | EVP, CHIEF BUS/STRAT OFFICER | 2,912 0.0002% | $154.72 | $450,545 | +12.72% | ||
| 2023-08-01 | Sale | CHAIRMAN OF THE BOARD AND CEO | 60,000 0.0035% | $148.58 | $8.91M | +8.24% | ||
| 2023-07-31 | Sale | CHAIRMAN OF THE BOARD AND CEO | 18,500 0.0011% | $149.15 | $2.76M | +7.42% | ||
| 2023-04-25 | Sale | SVP, US COMMERCIAL OPERATIONS | 6,130 0.0003% | $165.00 | $1.01M | -8.43% | ||
| 2023-04-17 | Sale | SVP, US COMMERCIAL OPERATIONS | 7,499 0.0004% | $161.67 | $1.21M | -6.32% | ||
| 2023-04-03 | Sale | 15,002 0.0008% | $160.03 | $2.4M | -5.03% | |||
| 2023-04-03 | Sale | 3,520 0.0002% | $160.00 | $563,200 | -5.03% | |||
| 2023-03-13 | Sale | 53,125 0.003% | $152.28 | $8.09M | +0.29% |
Insider Historical Profitability
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 60941 0.0034% | $176.94 | 1 | 8 | +37.99% |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 55903 0.0032% | $176.94 | 1 | 2 | +35.4% |
| Schumacher Laura J | Vice Chairman | 213003 0.0121% | $176.94 | 1 | 14 | +27.78% |
| CHASE WILLIAM J | EVP, Finance & Administration | 169552 0.0096% | $176.94 | 1 | 7 | +28.08% |
| Gosebruch Henry O | EVP, Chief Strategy Officer | 41623 0.0024% | $176.94 | 1 | 6 | +30.67% |
Institutional Investor Ownership
| The Vanguard Group | $31.03B | 9.65 | 170.38M | +6.22% | +$1.82B | 0.57 | |
| BlackRock | $26.03B | 8.1 | 142.96M | -0.16% | -$40.72M | 0.57 | |
| State Street | $14.2B | 4.42 | 77.97M | -0.29% | -$41.92M | 0.58 | |
| JPMorgan Chase | $9.33B | 2.9 | 51.26M | -1.08% | -$102.03M | 0.83 | |
| Capital International Investors | $8.76B | 2.72 | 48.1M | +6.91% | +$566.44M | 1.78 |